34.80
-0.20 (-0.57%)
| Previous Close | 35.00 |
| Open | 35.19 |
| Volume | 1,262,171 |
| Avg. Volume (3M) | 3,785,612 |
| Market Cap | 5,448,287,744 |
| Price / Earnings (Forward) | 23.31 |
| Price / Sales | 19.35 |
| Price / Book | 26.05 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -5.43% |
| Operating Margin (TTM) | 14.82% |
| Diluted EPS (TTM) | -0.100 |
| Quarterly Revenue Growth (YOY) | -49.40% |
| Quarterly Earnings Growth (YOY) | -96.60% |
| Total Debt/Equity (MRQ) | 132.35% |
| Current Ratio (MRQ) | 4.59 |
| Operating Cash Flow (TTM) | -28.09 M |
| Levered Free Cash Flow (TTM) | -45.57 M |
| Return on Assets (TTM) | -0.07% |
| Return on Equity (TTM) | -8.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | TG Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.63 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.50% |
| % Held by Institutions | 66.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 58.05%) | Buy |
| Median | 46.50 (33.62%) | |
| Low | 22.00 (Goldman Sachs, -36.78%) | Hold |
| Average | 42.50 (22.13%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 28.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 25 Nov 2024 | 43.00 (23.56%) | Buy | 34.61 |
| Goldman Sachs | 05 Nov 2024 | 22.00 (-36.78%) | Hold | 25.86 |
| HC Wainwright & Co. | 05 Nov 2024 | 55.00 (58.05%) | Buy | 25.86 |
| TD Cowen | 29 Oct 2024 | 50.00 (43.68%) | Buy | 25.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Nov 2024 | Announcement | TG Therapeutics to Participate in the Evercore HealthCONx Conference |
| 21 Nov 2024 | Announcement | TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ |
| 04 Nov 2024 | Announcement | TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance |
| 01 Nov 2024 | Announcement | TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |